Azimuth Capital Management LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,995 shares of the biopharmaceutical company’s stock after purchasing an additional 2,100 shares during the period. Azimuth Capital Management LLC’s holdings in Gilead Sciences were worth $2,665,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Athena Capital Advisors LLC purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $27,000. Capital Financial Planning LLC purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $27,000. Creative Financial Designs Inc. ADV increased its stake in shares of Gilead Sciences by 55.9% in the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 165 shares in the last quarter. Claybrook Capital LLC purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $32,000. Finally, Trustcore Financial Services LLC purchased a new position in shares of Gilead Sciences in the first quarter worth about $34,000. 78.78% of the stock is currently owned by institutional investors.
In other Gilead Sciences news, Director Richard James Whitley sold 9,534 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $65.48, for a total transaction of $624,286.32. Following the completion of the sale, the director now directly owns 34,669 shares in the company, valued at $2,270,126.12. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $65.07, for a total transaction of $175,689.00. Following the sale, the director now owns 57,560 shares of the company’s stock, valued at $3,745,429.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,602 shares of company stock valued at $1,863,445. 0.20% of the stock is currently owned by company insiders.
Several research firms have recently weighed in on GILD. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $87.00 target price on shares of Gilead Sciences in a research note on Tuesday, May 7th. Raymond James set a $83.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Friday, May 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Monday, May 6th. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Friday, May 24th. Finally, Goldman Sachs Group cut shares of Gilead Sciences from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $70.00 to $60.00 in a research note on Tuesday, May 28th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fifteen have given a buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and an average target price of $79.54.
Shares of NASDAQ:GILD opened at $66.78 on Thursday. The company has a market cap of $83.31 billion, a P/E ratio of 10.86, a PEG ratio of 0.80 and a beta of 1.09. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period in the previous year, the business posted $1.48 earnings per share. Gilead Sciences’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 6.6 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $2.52 annualized dividend and a yield of 3.77%. Gilead Sciences’s payout ratio is presently 40.98%.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Read More: Resistance Level
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.